IOmicron广SARS-CoV-2

Mengxiao Luo1, Runhong Zhou2, Bingjie Tang3

  • 1AIDS Institute, School of Clinical Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Pokfulam, Hong Kong SAR, People's Republic of China; Department of Microbiology, School of Clinical Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Pokfulam, Hong Kong SAR, People's Republic of China.

EBioMedicine
|September 28, 2024
PubMed
概括

新的广泛中和抗体 (bnAbs) 提供了对演变的SARS-CoV-2 Omicron变体如JN.1和KP.2的强有力的保护. 这些发现突出了下一代疫苗和抗体疗法针对COVID-19的潜在目标.